Telo Genomics Corp.

As of March 31, 2026, Telo Genomics Corp. carries a market capitalization of 3.11M, placing it among publicly traded companies globally. Its enterprise value stands at 3.32M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of March 31, 2026, Telo Genomics Corp. has 100.43M shares outstanding.

These figures are as of March 31, 2026.

As of March 31, 2026, Telo Genomics Corp. maintains a current ratio of 0.49, meaning it holds 0.5x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended March 31, 2026. Return on assets (ROA) is negative at -178.19, reflecting losses generated across the asset base. The company generates approximately - - in revenue per employee across its workforce of 8.00, a quick read on workforce productivity versus industry peers.

Over the twelve months ended March 31, 2026, Telo Genomics Corp. recorded an income tax benefit of -9,564.94 rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -1.46M and -1.45M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, Telo Genomics Corp.'s stock has declined approximately 10.84% over the past 52 weeks. The 50-day moving average sits at 0.03, while the 200-day moving average is 0.03.

Over the twelve months ended March 31, 2026, Telo Genomics Corp. generated - - in revenue and converted that into -1.45M in net income, yielding earnings per share of -0.01. EBITDA reached -1.42M, while operating income came in at -1.45M.

As of March 31, 2026, Telo Genomics Corp. holds 606,813.52 in cash and equivalents against 818,065.93 in total debt, resulting in a net debt position of 125,286.72. Total book value stands at -603,537.70, with working capital of -671,045.95 providing operational flexibility.

Telo Genomics Corp. produced -808,193.68 in operating cash flow over the twelve months ended March 31, 2026. After subtracting -139,961.35 in capital expenditures, free cash flow totaled -948,155.02 - equivalent to -0.01 per share.

These figures cover the twelve months ended March 31, 2026. Free cash flow yield is negative at -30.49: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow.

Telo Genomics Corp.'s most recent stock split took place on November 22, 2019 with a 5:1 split ratio.

As of March 31, 2026, Telo Genomics Corp. has an Altman Z-Score of -42.80, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.